| Anna Paul Thottan, MD | |
|
24035 Three Notch Rd, Hollywood, MD 20636-4871 | |
| (301) 373-7900 | |
| Not Available |
| Full Name | Anna Paul Thottan |
|---|---|
| Gender | Female |
| Speciality | Endocrinology |
| Experience | 15 Years |
| Location | 24035 Three Notch Rd, Hollywood, Maryland |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033498456 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RE0101X | Internal Medicine - Endocrinology, Diabetes & Metabolism | D0080596 (Maryland) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Medstar Washington Hospital Center | Washington, DC | Hospital |
| Medstar Saint Mary's Hospital | Leonardtown, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Medstar Medical Group - Southern Maryland Llc | 1355667056 | 195 |
| Medstar Medical Group - Southern Maryland Llc | 1355667056 | 195 |
News Archive
MedCath Corporation, a healthcare provider focused on high acuity healthcare services, predominately the diagnosis and treatment of cardiovascular disease, today announced its unaudited operating results for its first quarter of fiscal 2010, which ended December 31, 2009.
In an advance that could lead to better identification of malignant pediatric adrenocortical tumors, and ultimately to better treatment, researchers have mapped the "genomic landscape" of these rare childhood tumors. Their genomic mapping has revealed unprecedented details, not only of the aberrant genetic and chromosomal changes that drive the cancer, but the sequence of those changes that trigger it.
Quick-Med Technologies, Inc. announced today that it has successfully completed its joint development program with Foster Corporation, a member of PolyMedex Discovery Group, to collaborate in applying Quick-Med's proprietary NIMBUS® technology to thermoplastics for catheters and other medical product applications.
Study shows that more than 40 percent of patients who initially had received a positive result on a fecal occult blood test (FOBT) did not receive appropriate diagnostic follow-up tests such as a colonoscopy or barium enema in 2002.
N30 Pharmaceuticals, Inc. announced today that it has begun oral dosing of N91115 in a Phase 1 clinical trial. N91115, a novel inhibitor of S-nitrosoglutathione reductase (GSNOR), is being developed for the treatment of cystic fibrosis (CF).
› Verified 9 days ago
| Entity Name | Medstar Medical Group - Southern Maryland Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831592211 PECOS PAC ID: 1355667056 Enrollment ID: O20150223001281 |
News Archive
MedCath Corporation, a healthcare provider focused on high acuity healthcare services, predominately the diagnosis and treatment of cardiovascular disease, today announced its unaudited operating results for its first quarter of fiscal 2010, which ended December 31, 2009.
In an advance that could lead to better identification of malignant pediatric adrenocortical tumors, and ultimately to better treatment, researchers have mapped the "genomic landscape" of these rare childhood tumors. Their genomic mapping has revealed unprecedented details, not only of the aberrant genetic and chromosomal changes that drive the cancer, but the sequence of those changes that trigger it.
Quick-Med Technologies, Inc. announced today that it has successfully completed its joint development program with Foster Corporation, a member of PolyMedex Discovery Group, to collaborate in applying Quick-Med's proprietary NIMBUS® technology to thermoplastics for catheters and other medical product applications.
Study shows that more than 40 percent of patients who initially had received a positive result on a fecal occult blood test (FOBT) did not receive appropriate diagnostic follow-up tests such as a colonoscopy or barium enema in 2002.
N30 Pharmaceuticals, Inc. announced today that it has begun oral dosing of N91115 in a Phase 1 clinical trial. N91115, a novel inhibitor of S-nitrosoglutathione reductase (GSNOR), is being developed for the treatment of cystic fibrosis (CF).
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Anna Paul Thottan, MD 86 Elmira St, Apt 2, Brighton, MA 02135-2851 Ph: (508) 309-7022 | Anna Paul Thottan, MD 24035 Three Notch Rd, Hollywood, MD 20636-4871 Ph: (301) 373-7900 |
News Archive
MedCath Corporation, a healthcare provider focused on high acuity healthcare services, predominately the diagnosis and treatment of cardiovascular disease, today announced its unaudited operating results for its first quarter of fiscal 2010, which ended December 31, 2009.
In an advance that could lead to better identification of malignant pediatric adrenocortical tumors, and ultimately to better treatment, researchers have mapped the "genomic landscape" of these rare childhood tumors. Their genomic mapping has revealed unprecedented details, not only of the aberrant genetic and chromosomal changes that drive the cancer, but the sequence of those changes that trigger it.
Quick-Med Technologies, Inc. announced today that it has successfully completed its joint development program with Foster Corporation, a member of PolyMedex Discovery Group, to collaborate in applying Quick-Med's proprietary NIMBUS® technology to thermoplastics for catheters and other medical product applications.
Study shows that more than 40 percent of patients who initially had received a positive result on a fecal occult blood test (FOBT) did not receive appropriate diagnostic follow-up tests such as a colonoscopy or barium enema in 2002.
N30 Pharmaceuticals, Inc. announced today that it has begun oral dosing of N91115 in a Phase 1 clinical trial. N91115, a novel inhibitor of S-nitrosoglutathione reductase (GSNOR), is being developed for the treatment of cystic fibrosis (CF).
› Verified 9 days ago
Charudatta Wankhade, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 24035 Three Notch Rd, Hollywood, MD 20636 Phone: 301-373-7900 Fax: 301-373-6900 | |
Vinaychandra Shah, Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 24035 Three Notch Rd, Hollywood, MD 20636 Phone: 301-373-7400 Fax: 301-373-6400 | |
Bhasker Jhaveri, Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 24035 Three Notch Rd, Hollywood, MD 20636 Phone: 301-373-7100 Fax: 301-373-6100 | |
Amish Shah, Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 24035 Three Notch Rd, Hollywood, MD 20636 Phone: 301-373-7400 Fax: 301-373-6400 | |
Kiran Mehta, Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 24035 Three Notch Rd, Hollywood, MD 20636 Phone: 301-373-7900 Fax: 301-373-6900 | |
Dr. Bryan John Lebude, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 24035 Three Notch Rd, Hollywood, MD 20636 Phone: 301-373-7318 |